Compare $IMNM vs $RXRX | Chartloom

Compare

$IMNM vs $RXRX

Immunome Inc · Recursion Pharmaceuticals Inc

IMNM

Immunome Inc

RXRX

Recursion Pharmaceuticals Inc

Compare $IMNM vs $RXRX

Comparing Immunome Inc and Recursion Pharmaceuticals Inc

IMNMImmunome Inc

RXRXRecursion Pharmaceuticals Inc

IMNMImmunome Inc

Market cap

$2.21B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

127.50x

Rev growth (TTM)

-100.0%

YTD performance

-6.1%

52W performance

39.5%

FCF yield

-10.3%

RXRXRecursion Pharmaceuticals Inc

Market cap

$2.31B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

44.44x

Rev growth (TTM)

-15.1%

YTD performance

3.8%

52W performance

-28.4%

FCF yield

-15.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IMNM

RXRX

Detailed metrics comparison

IMNM

Immunome Inc

RXRX

Recursion Pharmaceuticals Inc

Market Cap

IMNM$2.21B

RXRX$2.31B

Enterprise Value

IMNM$2.00B

RXRX$1.78B

Price

IMNM$19.55

RXRX$4.36

P/E Ratio

IMNMN/A

RXRXN/A

P/S Ratio

IMNM188.56x

RXRX42.12x

EV/Sales

IMNM171.27x

RXRX32.43x

EV/EBITDA

IMNM0.00x

RXRX0.00x

P/B Ratio

IMNM4.52x

RXRX2.41x

P/FCF Ratio

IMNMN/A

RXRXN/A

EV/FCF

IMNM-8.75x

RXRX-5.05x

PEG Ratio

IMNMN/A

RXRXN/A

Forward P/E (NTM)

IMNMN/A

RXRXN/A

Forward P/S (NTM)

IMNM127.50x

RXRX44.44x

Revenue (TTM)

IMNM$0

RXRX$55M

Revenue Growth (YoY)

IMNM-100.0%

RXRX-15.1%

Forward Rev Growth

IMNM15247.2%

RXRX31.0%

Gross Margin (TTM)

IMNM0.0%

RXRX3.5%

Operating Margin (TTM)

IMNM0.0%

RXRX0.0%

EBITDA Margin (TTM)

IMNM0.0%

RXRX-848.9%

Net Margin (TTM)

IMNM0.0%

RXRX-945.9%

FCF Margin (TTM)

IMNMN/A

RXRX-642.2%

Net Income (TTM)

IMNM$-254M

RXRX$-519M

FCF (TTM)

IMNM$-228M

RXRX$-352M

EPS (TTM)

IMNM-$2.25

RXRX-$0.97

ROE (TTM)

IMNM-5056.0%

RXRX-5041.0%

ROA (TTM)

IMNM-4693.0%

RXRX-3825.0%

ROIC (TTM)

IMNM-5056.0%

RXRX-4956.0%

Cash

IMNM$218M

RXRX$546M

Debt

IMNM$0

RXRX$14M

Net Cash/Debt

IMNM$218M

RXRX$531M

Current Ratio (TTM)

IMNM15.08x

RXRX5.03x

Quick Ratio (TTM)

IMNM14.56x

RXRX4.96x

Debt/Equity (TTM)

IMNM0.00x

RXRX0.02x

Debt/Assets (TTM)

IMNM0.0%

RXRX0.0%

Interest Coverage (TTM)

IMNMN/A

RXRXN/A

Net Debt/EBITDA (TTM)

IMNM0.00x

RXRX0.00x

Beta

IMNM2.65

RXRX1.18

52W Performance

IMNM39.5%

RXRX-28.4%

YTD Performance

IMNM-6.1%

RXRX3.8%

% from 52W High

IMNM-35.0%

RXRX-39.3%

% from 52W Low

IMNM44.9%

RXRX57.4%

Asset Turnover (TTM)

IMNM0.04x

RXRX0.04x

FCF Yield (TTM)

IMNM-10.3%

RXRX-15.2%

Earnings Yield (TTM)

IMNM-11.5%

RXRX-22.5%

Dividend Yield (TTM)

IMNMN/A

RXRXN/A

Rule of 40

IMNM-100.0

RXRX-657.3

EV/GP/RG

IMNMN/A

RXRX29.99

Ticker research

View IMNM research View RXRX research

Metric	IMNM Immunome Inc	RXRX Recursion Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.21B	$2.31B
Enterprise Value	$2.00B	$1.78B
Price	$19.55	$4.36
P/E Ratio	N/A	N/A
P/S Ratio	188.56x	42.12x
EV/Sales	171.27x	32.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.52x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.75x	-5.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	127.50x	44.44x
Revenue & Growth
Revenue (TTM)	$0	$55M
Revenue Growth (YoY)	-100.0%	-15.1%
Forward Rev Growth	15247.2%	31.0%
Profitability
Gross Margin (TTM)	0.0%	3.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-848.9%
Net Margin (TTM)	0.0%	-945.9%
FCF Margin (TTM)	N/A	-642.2%
Net Income (TTM)	$-254M	$-519M
FCF (TTM)	$-228M	$-352M
EPS (TTM)	-$2.25	-$0.97
ROE (TTM)	-5056.0%	-5041.0%
ROA (TTM)	-4693.0%	-3825.0%
ROIC (TTM)	-5056.0%	-4956.0%
Financial Health
Cash	$218M	$546M
Debt	$0	$14M
Net Cash/Debt	$218M	$531M
Current Ratio (TTM)	15.08x	5.03x
Quick Ratio (TTM)	14.56x	4.96x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.65	1.18
52W Performance	39.5%	-28.4%
YTD Performance	-6.1%	3.8%
% from 52W High	-35.0%	-39.3%
% from 52W Low	44.9%	57.4%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.04x
FCF Yield (TTM)	-10.3%	-15.2%
Earnings Yield (TTM)	-11.5%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	-657.3
EV/GP/RG	N/A	29.99
Ticker research	View IMNM research	View RXRX research

Valuation

P/S Ratio

RXRX

42.12x

IMNM

188.56x

EV/FCF

IMNM

-8.75x

RXRX

-5.05x

Growth & revenue

Revenue Growth TTM

RXRX

-15.1%

IMNM

-100.0%

Forward Revenue Growth

IMNM

15247.2%

RXRX

31.0%

Profitability & performance

Gross Margin

RXRX

3.5%

IMNM

0.0%

ROE

RXRX

-5041.0%

IMNM

-5056.0%

FCF Yield %

IMNM

-10.3%

RXRX

-15.2%

52-Week Performance

IMNM

39.5%

RXRX

-28.4%

Detailed metrics comparison

IMNM

Immunome Inc

RXRX

Recursion Pharmaceuticals Inc

Market Cap

IMNM$2.21B

RXRX$2.31B

Enterprise Value

IMNM$2.00B

RXRX$1.78B

Price

IMNM$19.55

RXRX$4.36

P/E Ratio

IMNMN/A

RXRXN/A

P/S Ratio

IMNM188.56x

RXRX42.12x

EV/Sales

IMNM171.27x

RXRX32.43x

EV/EBITDA

IMNM0.00x

RXRX0.00x

P/B Ratio

IMNM4.52x

RXRX2.41x

P/FCF Ratio

IMNMN/A

RXRXN/A

EV/FCF

IMNM-8.75x

RXRX-5.05x

PEG Ratio

IMNMN/A

RXRXN/A

Forward P/E (NTM)

IMNMN/A

RXRXN/A

Forward P/S (NTM)

IMNM127.50x

RXRX44.44x

Revenue (TTM)

IMNM$0

RXRX$55M

Revenue Growth (YoY)

IMNM-100.0%

RXRX-15.1%

Forward Rev Growth

IMNM15247.2%

RXRX31.0%

Gross Margin (TTM)

IMNM0.0%

RXRX3.5%

Operating Margin (TTM)

IMNM0.0%

RXRX0.0%

EBITDA Margin (TTM)

IMNM0.0%

RXRX-848.9%

Net Margin (TTM)

IMNM0.0%

RXRX-945.9%

FCF Margin (TTM)

IMNMN/A

RXRX-642.2%

Net Income (TTM)

IMNM$-254M

RXRX$-519M

FCF (TTM)

IMNM$-228M

RXRX$-352M

EPS (TTM)

IMNM-$2.25

RXRX-$0.97

ROE (TTM)

IMNM-5056.0%

RXRX-5041.0%

ROA (TTM)

IMNM-4693.0%

RXRX-3825.0%

ROIC (TTM)

IMNM-5056.0%

RXRX-4956.0%

Cash

IMNM$218M

RXRX$546M

Debt

IMNM$0

RXRX$14M

Net Cash/Debt

IMNM$218M

RXRX$531M

Current Ratio (TTM)

IMNM15.08x

RXRX5.03x

Quick Ratio (TTM)

IMNM14.56x

RXRX4.96x

Debt/Equity (TTM)

IMNM0.00x

RXRX0.02x

Debt/Assets (TTM)

IMNM0.0%

RXRX0.0%

Interest Coverage (TTM)

IMNMN/A

RXRXN/A

Net Debt/EBITDA (TTM)

IMNM0.00x

RXRX0.00x

Beta

IMNM2.65

RXRX1.18

52W Performance

IMNM39.5%

RXRX-28.4%

YTD Performance

IMNM-6.1%

RXRX3.8%

% from 52W High

IMNM-35.0%

RXRX-39.3%

% from 52W Low

IMNM44.9%

RXRX57.4%

Asset Turnover (TTM)

IMNM0.04x

RXRX0.04x

FCF Yield (TTM)

IMNM-10.3%

RXRX-15.2%

Earnings Yield (TTM)

IMNM-11.5%

RXRX-22.5%

Dividend Yield (TTM)

IMNMN/A

RXRXN/A

Rule of 40

IMNM-100.0

RXRX-657.3

EV/GP/RG

IMNMN/A

RXRX29.99

Ticker research

View IMNM research View RXRX research

Metric	IMNM Immunome Inc	RXRX Recursion Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.21B	$2.31B
Enterprise Value	$2.00B	$1.78B
Price	$19.55	$4.36
P/E Ratio	N/A	N/A
P/S Ratio	188.56x	42.12x
EV/Sales	171.27x	32.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.52x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.75x	-5.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	127.50x	44.44x
Revenue & Growth
Revenue (TTM)	$0	$55M
Revenue Growth (YoY)	-100.0%	-15.1%
Forward Rev Growth	15247.2%	31.0%
Profitability
Gross Margin (TTM)	0.0%	3.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-848.9%
Net Margin (TTM)	0.0%	-945.9%
FCF Margin (TTM)	N/A	-642.2%
Net Income (TTM)	$-254M	$-519M
FCF (TTM)	$-228M	$-352M
EPS (TTM)	-$2.25	-$0.97
ROE (TTM)	-5056.0%	-5041.0%
ROA (TTM)	-4693.0%	-3825.0%
ROIC (TTM)	-5056.0%	-4956.0%
Financial Health
Cash	$218M	$546M
Debt	$0	$14M
Net Cash/Debt	$218M	$531M
Current Ratio (TTM)	15.08x	5.03x
Quick Ratio (TTM)	14.56x	4.96x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.65	1.18
52W Performance	39.5%	-28.4%
YTD Performance	-6.1%	3.8%
% from 52W High	-35.0%	-39.3%
% from 52W Low	44.9%	57.4%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.04x
FCF Yield (TTM)	-10.3%	-15.2%
Earnings Yield (TTM)	-11.5%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	-657.3
EV/GP/RG	N/A	29.99
Ticker research	View IMNM research	View RXRX research